Compare SE & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SE | NTRA |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9B | 45.3B |
| IPO Year | 2017 | 2015 |
| Metric | SE | NTRA |
|---|---|---|
| Price | $117.69 | $338.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 15 |
| Target Price | $173.69 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 4.3M | 1.4M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | $32.31 | $18.08 |
| Revenue Next Year | $21.53 | $19.65 |
| P/E Ratio | $49.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $77.05 | $157.43 |
| 52 Week High | $199.30 | $340.96 |
| Indicator | SE | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 70.14 |
| Support Level | $81.31 | $187.64 |
| Resistance Level | $131.07 | N/A |
| Average True Range (ATR) | 4.08 | 10.11 |
| MACD | -0.73 | 1.46 |
| Stochastic Oscillator | 25.21 | 86.21 |
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid consumer-to-consumer and business-to-consumer marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue-generating game. Sea's third business, Monee, provides lending, payment, digital banking, and insurance services. As of March 2025, Forrest Li, the founder, chair, and CEO, owned 59.1% of the voting power. Tencent owned 18.5% of issued shares with no voting power.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.